Table 2.
Multivariate analysis of prognostic factors for all 318 pairs of stage III-IVB NPC patients (except T3-4N0) with or without IC.
| Endpoints | Variable | HR (95% CI) | Pa |
|---|---|---|---|
| OS | Age | 1.849 (1.206-2.834) | 0.005 |
| N category, N2 vs. N1 | 2.007 (1.274-3.161) | 0.003 | |
| Overall stage | 2.299 (1.448-3.652) | < 0.001 | |
| Pre-DNA | 1.848 (1.155-2.957) | 0.01 | |
| IC | 0.595(0.397-0.891) | 0.012 | |
| DMFS | N category, N2 vs. N1 | 1.809 (1.113-2.941) | 0.017 |
| Overall stage | 1.814 (1.084-3.037) | 0.023 | |
| Pre-DNA | 2.850 (1.630-4.985) | < 0.001 | |
| IC | 0.684 (0.446-1.048) | 0.081 | |
| DFS | Age | 1.408 (1.006-1.971) | 0.046 |
| N category, N2 vs. N1 | 1.623 (1.116-2.360) | 0.011 | |
| Overall stage | 1.743 (1.181-2.573) | 0.005 | |
| Pre-DNA | 1.591 (1.103-2.293) | 0.013 | |
| IC | 0.627(0.451-0.872) | 0.006 | |
| LRRFS | IC | 0.634(0.378-1.063) | 0.084 |
Abbreviations: NPC = nasopharyngeal carcinoma; IC = neoadjuvant chemotherapy; HR = hazard ratio; CI = confidence interval; OS = overall survival; DMFS = distant metastasis-free survival; DFS = disease-free survival; LRRFS = locoregional relapse-free survival; Pre-DNA = pre-treatment Epstein-Barr virus DNA.
a: Multivariate P-values were calculated using an adjusted Cox proportional-hazards model with backward elimination and the following parameters: age (> 45y vs. ≤ 45y), gender (male vs. female), concurrent chemotherapy (yes vs. no), smoking (yes vs. no), drinking (yes vs. no), T category (T1-2 vs. T3-4), N category (N2 vs. N1, N3 vs. N1), overall stage (III vs. IVA-B), pre-DNA (≥ 1595 copies/ml vs. < 1595 copies/ml) and IC (yes vs. no).